NCT05303740View on ClinicalTrials.gov

Anlotinib Retrospective Study for Esophageal Cancer

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions
Esophageal Neoplasms
Interventions
DRUG

Anlotinib

This is an observational study.

Trial Locations (1)

450000

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Feng Wang

OTHER

NCT05303740 - Anlotinib Retrospective Study for Esophageal Cancer | Biotech Hunter | Biotech Hunter